Filings (90d)
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies ARCH Venture Fund XIII, L.P. files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- ARCH Venture Partners IX, LLC - $12.50M in LYEL purchases and sales in the last 12 months
- Lynn Seely - $353K in LYEL purchases and sales in the last 12 months
- Gary K. Lee - $72K in LYEL purchases and sales in the last 12 months
- Stephen J. Hill - $51K in LYEL purchases and sales in the last 12 months
- David Shook - $31K in LYEL purchases and sales in the last 12 months
- Veronica Sanchez Bulis - $23K in LYEL purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
What is ARCH Venture Fund XIII, L.P.?
ARCH Venture Fund XIII, L.P. is an investment firm, tracked as 10% Owner of Lyell Immunopharma, Inc. (LYEL). InsiderAlpha holds 1 primary Form 4 filing for it, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did ARCH Venture Fund XIII, L.P. last file a Form 4?
The only primary Form 4 on record is dated 9 March 2026.
Has ARCH Venture Fund XIII, L.P. been buying or selling stock?
Recorded transactions: 1 open-market purchase ($12.50M) and 0 open-market sales across all tracked filings.
